✦ LIBER ✦

MEDICAL COSTS AVOIDED FOR PREVENTION OF STROKE WITH USE OF NOACS: ESTIMATES FOR THE REAL-WORLD

✍ Scribed by Amin, Alpesh; Stokes, Michael; Makenbaeva, Dinara; Wiederkehr, Daniel; Gatt, Elyse; Wu, Ning; Lawrence, John; Squibb, Bristol-Myers

Book ID: 122291181
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 235 KB
Volume: 63
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(14)60330-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MY APPROACH to the use of NOACs for stro

MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation*

✍ Lip, Gregory Y.H. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 419 KB

Estimating cost of in-patient medical ca

Estimating cost of in-patient medical care for stroke using Casemix data

✍ Nor Azlin Mohd Nordin, Amrizal Muhamad Nur, Saperi Sulong… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 74 KB

Use of antiplatelet agents to prevent st

Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?

✍ Neil E. Schwartz; Gregory W. Albers 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 150 KB

Estimated medical cost reductions associ

Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population

✍ Amin, Alpesh; Stokes, Michael; Makenbaeva, Dinara; Wiederkehr, Daniel; Wu, Ning; 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 166 KB

The cost–effectiveness of rivaroxaban fo

The cost–effectiveness of rivaroxaban for the prevention of stroke in patients with atrial fibrillation (AF) in Turkey

✍ Marmarali, B.; Ozdemir, O.; Bozkurt, K.; Demir, M.; Ince, B.; Kultursay, H.; Ong 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Methods for developing useful estimates

Methods for developing useful estimates of the costs associated with birth defects

✍ Amy P. Case; Mark A. Canfield 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

## Abstract ## BACKGROUND: Cost estimates for birth defects are useful to policy makers in deciding the best use of resources to prevent these conditions. Much of the effort in this area has focused on spina bifida, in part because cost savings can be estimated from folic acid–preventable cases. H